Burning Rock Biotech (NASDAQ:BNR) Director Acquires 111,110 Shares of Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 111,110 shares of Burning Rock Biotech stock in a transaction dated Tuesday, June 16th. The stock was purchased at an average price of $9.00 per share, for a total transaction of $999,990.00. Following the purchase, the director directly owned 18,018,546 shares in the company, valued at $162,166,914. This represents a 0.62% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were bought at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Stock Up 7.0%

Shares of NASDAQ BNR opened at $8.96 on Thursday. The firm has a market capitalization of $94.26 million, a PE ratio of -10.93 and a beta of 1.33. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.22 and a 1 year high of $41.72. The firm’s 50-day moving average is $12.79 and its 200-day moving average is $20.08.

Burning Rock Biotech (NASDAQ:BNR) last posted its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $2.09. The business had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of Burning Rock Biotech in the 4th quarter valued at approximately $220,000. Renaissance Technologies LLC grew its stake in shares of Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Prospera Financial Services Inc increased its holdings in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the last quarter. Finally, Crcm LP increased its holdings in Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares during the last quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BNR shares. Wall Street Zen lowered shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.